These changes, in turn, dysregulate CD34+ cell differentiation and also affect the transcriptional regulation of growth factors, such as TGFβ2, which is involved in the proliferation of lineage-committed myeloid progenitors in hematopoietic malignancies such as leukemia (Shah et al., 2011). The gene discussed is CD34; the disease is leukemia.